Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Chromadex Corp is a biotechnology business based in the US. Chromadex shares (CDXC) are listed on the NASDAQ and all prices are listed in US Dollars. Chromadex employs 115 staff and has a trailing 12-month revenue of around $69.1 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $1.21 |
|---|---|
| 52-week range | $1.19 - $6.98 |
| 50-day moving average | $1.62 |
| 200-day moving average | $2.29 |
| Wall St. target price | $6.11 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.40 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.21 from 2022-09-27
| 1 week (2022-09-21) | -11.68% |
|---|---|
| 1 month (2022-08-29) | -16.55% |
| 3 months (2022-06-29) | -30.86% |
| 6 months (2022-03-29) | -53.82% |
| 1 year (2021-09-29) | -80.00% |
|---|---|
| 2 years (2020-09-29) | -69.90% |
| 3 years (2019-09-27) | 4.08 |
| 5 years (2017-09-28) | 4.34 |
| Revenue TTM | $69.1 million |
|---|---|
| Gross profit TTM | $41.5 million |
| Return on assets TTM | -31.43% |
| Return on equity TTM | -90.01% |
| Profit margin | -41.01% |
| Book value | $0.30 |
| Market capitalisation | $82.7 million |
TTM: trailing 12 months
We're not expecting Chromadex to pay a dividend over the next 12 months.
Chromadex's shares were split on a 1:3 basis on 12 April 2016. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chromadex shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Chromadex shares which in turn could have impacted Chromadex's share price.
Over the last 12 months, Chromadex's shares have ranged in value from as little as $1.19 up to $6.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chromadex's is 1.7331. This would suggest that Chromadex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN. com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.